1360802-78-3Relevant academic research and scientific papers
CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
Bard, Jonathan A.,Brown, Christopher J.,Chen, Xuemei,Clark-Frew, Daniel,Coe, Samuel,Conlon, Mike,Davis, Randall,Dominguez, Celia,Ensor, Samantha,Esposito, Simone,Gai, Xinjie,Green, Samantha,Greenaway, Catherine,Haber, James,Halldin, Christer,Hayes, Sarah,He?mann, Manuela,Herbst, Todd,Herrmann, Frank,Hsai, Ming Min,Johnson, Peter D.,Khetarpal, Vinod,Kotey, Adrian,Lee, Matthew R.,Liu, Longbin,Mangette, John E.,Mills, Matthew R.,Monteagudo, Edith,Moren, Anton Forsberg,Mrzljak, Ladislav,Munoz-Sanjuan, Ignacio,Nag, Sangram,Nibbio, Martina,Orsatti, Laura,Prime, Michael E.,Schaertl, Sabine,Scheich, Christoph,Sproston, Joanne,Stepanov, Vladimir,Varn?s, Katarina,Varrone, Andrea,Wityak, John
, p. 12003 - 12021 (2021/09/02)
The expanded polyglutamine-containing mutant huntingtin (mHTT) protein is implicated in neuronal degeneration of medium spiny neurons in Huntington's disease (HD) for which multiple therapeutic approaches are currently being evaluated to eliminate or redu
HETEROCYCLIC COMPOUND
-
Paragraph 0336, (2016/09/26)
The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS
-
Page/Page column 70-71, (2012/03/11)
Described herein are compounds of formula I. The compounds of formula I act as DGAT-1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
